Thompson Siegel & Walmsley LLC Has $7.90 Million Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,059 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,626 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.45% of ANI Pharmaceuticals worth $7,899,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the period. UBS Group AG grew its stake in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the period. Geode Capital Management LLC grew its stake in ANI Pharmaceuticals by 4.2% during the fourth quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after purchasing an additional 19,258 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in ANI Pharmaceuticals during the third quarter worth approximately $32,992,000. Finally, Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after purchasing an additional 85,745 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:ANIP opened at $76.71 on Tuesday. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 19.42 and a beta of 0.44. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 12-month low of $58.70 and a 12-month high of $99.50. The business’s 50 day moving average is $78.77 and its 200 day moving average is $79.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.96 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director directly owned 38,432 shares in the company, valued at approximately $3,098,772.16. This represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 88,950 shares of company stock valued at $6,900,618 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.